NVCR vs. EBS
NVCR (NovoCure Limited) and EBS (Emergent BioSolutions Inc.) are both stocks. Both are in the Healthcare sector — NVCR in Medical Instruments & Supplies, EBS in Drug Manufacturers - Specialty & Generic. Over the past 10 years, NVCR returned 3.89%/yr vs -11.05%/yr for EBS. At a 0.31 correlation, their price movements are largely independent.
Performance
NVCR vs. EBS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVCR achieves a 16.40% return, which is significantly higher than EBS's -35.44% return. Over the past 10 years, NVCR has outperformed EBS with an annualized return of 3.89%, while EBS has yielded a comparatively lower -11.05% annualized return.
NVCR
- 1D
- 2.24%
- 1M
- -17.58%
- YTD
- 16.40%
- 6M
- 11.98%
- 1Y
- -13.13%
- 3Y*
- -28.69%
- 5Y*
- -41.58%
- 10Y*
- 3.89%
EBS
- 1D
- -5.34%
- 1M
- -12.60%
- YTD
- -35.44%
- 6M
- -36.82%
- 1Y
- 18.75%
- 3Y*
- -4.87%
- 5Y*
- -33.93%
- 10Y*
- -11.05%
NVCR vs. EBS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NVCR NovoCure Limited | 16.40% | -56.61% | 99.60% | -79.65% | -2.30% | -56.61% | 105.34% | 151.70% | 65.74% | 157.32% |
EBS Emergent BioSolutions Inc. | -35.44% | 29.29% | 298.33% | -79.68% | -72.83% | -51.48% | 66.08% | -8.99% | 27.57% | 41.50% |
Correlation
The correlation between NVCR and EBS is 0.36, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.36 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.32 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.35 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.32 |
Correlation (All Time) Calculated using the full available price history since Oct 2, 2015 | 0.31 |
Fundamentals
NVCR:
-$1.54
EBS:
-$0.37
NVCR:
2.51
EBS:
0.49
NVCR:
$674.41M
EBS:
$676.80M
NVCR:
$507.13M
EBS:
$292.40M
NVCR:
-$164.04M
EBS:
$126.60M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVCR vs. EBS — Risk / Return Rank
NVCR
EBS
NVCR vs. EBS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for NovoCure Limited (NVCR) and Emergent BioSolutions Inc. (EBS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NVCR | EBS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.40 | ||
| Sortino ratioReturn per unit of downside risk | -0.72 | ||
| Omega ratioGain probability vs. loss probability | 1.04 | 1.14 | -0.10 |
| Calmar ratioReturn relative to maximum drawdown | -0.29 | 0.43 | -0.71 |
| Martin ratioReturn relative to average drawdown | -0.45 | 0.75 | -1.19 |
Loading charts...
Drawdowns
NVCR vs. EBS - Drawdown Comparison
The maximum NVCR drawdown since its inception was -95.55%, roughly equal to the maximum EBS drawdown of -98.89%. Use the drawdown chart below to compare losses from any high point for NVCR and EBS.
Loading charts...
Drawdown Indicators
| NVCR | EBS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.55% | -98.89% | +3.34% |
Max Drawdown (1Y)Largest decline over 1 year | -45.67% | -44.24% | -1.43% |
Max Drawdown (3Y)Largest decline over 3 years | -76.32% | -82.23% | +5.91% |
Max Drawdown (5Y)Largest decline over 5 years | -95.52% | -97.73% | +2.21% |
Max Drawdown (10Y)Largest decline over 10 years | -95.55% | -98.89% | +3.34% |
Current DrawdownCurrent decline from peak | -93.33% | -94.09% | +0.76% |
Average DrawdownAverage peak-to-trough decline | -52.36% | -41.27% | -11.09% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 29.44% | 25.21% | +4.23% |
Volatility
NVCR vs. EBS - Volatility Comparison
NovoCure Limited (NVCR) has a higher volatility of 29.54% compared to Emergent BioSolutions Inc. (EBS) at 17.32%. This indicates that NVCR's price experiences larger fluctuations and is considered to be riskier than EBS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVCR | EBS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 29.54% | 17.32% | +12.22% |
Volatility (6M)Calculated over the trailing 6-month period | 62.03% | 48.56% | +13.47% |
Volatility (1Y)Calculated over the trailing 1-year period | 76.75% | 82.46% | -5.71% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 80.23% | 102.32% | -22.09% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 72.19% | 79.78% | -7.59% |
Dividends
NVCR vs. EBS - Dividend Comparison
Neither NVCR nor EBS has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
EBS Emergent BioSolutions Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 5.65% |
NVCR NovoCure Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
NVCR vs. EBS - Financials Comparison
This section allows you to compare key financial metrics between NovoCure Limited and Emergent BioSolutions Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVCR vs. EBS - Profitability Comparison
NVCR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, NovoCure Limited reported a gross profit of 135.13M and revenue of 174.06M. Therefore, the gross margin over that period was 77.6%.
EBS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Emergent BioSolutions Inc. reported a gross profit of 61.20M and revenue of 156.10M. Therefore, the gross margin over that period was 39.2%.
NVCR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, NovoCure Limited reported an operating income of -67.42M and revenue of 174.06M, resulting in an operating margin of -38.7%.
EBS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Emergent BioSolutions Inc. reported an operating income of 0.00 and revenue of 156.10M, resulting in an operating margin of 0.0%.
NVCR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, NovoCure Limited reported a net income of -71.14M and revenue of 174.06M, resulting in a net margin of -40.9%.
EBS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Emergent BioSolutions Inc. reported a net income of 0.00 and revenue of 156.10M, resulting in a net margin of 0.0%.
Frequently Asked Questions
NVCR and EBS have a correlation of 0.36, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NVCR has higher volatility (29.54%) compared to EBS (17.32%). In terms of maximum drawdown, NVCR dropped -95.55% vs EBS's -98.89%.
EBS currently has the higher Sharpe Ratio (0.23 vs -0.17), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVCR and EBS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer